You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

17 Results
Guidelines and Advice
Status: Current
ID: 5-11
Version: 2
Jan 2022
Guidelines and Advice
Status: Archived
ID: 43096
Feb 2018
Drug
Other Name(s): Cosmegen®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Jan 2022
Drug
Other Name(s): Xalkori®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Jan 2022
Regimen
Cancer Type:
Gynecologic, 
Uterine Sarcoma, 
Sarcoma, 
Uterine
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
ifosfamide,
mesna
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Feb 2018
Regimen
Cancer Type:
Head and Neck
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant
Drugs Used:
CARBOplatin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Feb 2018
Regimen
Cancer Type:
Sarcoma, 
Ewing's, 
Soft Tissue
Show More Show more tags
, Show Less Show fewer tags
Intent: Neoadjuvant, Adjuvant, Palliative
Drugs Used:
etoposide,
ifosfamide,
mesna
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Feb 2018
Cancer facts
Feb 2018
Regimen
Cancer Type:
Hematologic, 
Lymphoma - T-cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative
Funding:
New Drug Funding Program
    Pegaspargase - Extranodal Natural Killer/T-cell Lymphoma
ODB - General Benefit
    dexamethasone
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
pegaspargase,
gemcitabine,
CISplatin,
dexamethasone
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jan 2022
Drug
Other Name(s): Kisqali™
Quick Link(s):
Drug Monograph, Patient Info Sheet
Jan 2022
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Intermediate Grade, 
Lymphoma - T-cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative, Palliative
Funding:
New Drug Funding Program
    Brentuximab Vedotin - In Combination with Chemotherapy for Previously Untreated Peripheral T-cell Lymphoma (PTCL)
ODB - General Benefit
    prednisone
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
brentuximab vedotin,
cyclophosphamide,
DOXOrubicin,
prednisone
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jan 2022
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Intermediate Grade, 
Lymphoma - T-cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative, Palliative
Funding:
ODB - General Benefit
    prednisone
ODB - General Benefit
    etoposide - oral capsules
New Drug Funding Program
    Brentuximab Vedotin - In Combination with Chemotherapy for Previously Untreated Peripheral T-cell Lymphoma (PTCL)
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
brentuximab vedotin,
cyclophosphamide,
etoposide,
prednisone
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jan 2022

Pages